Expression of Interleukin-17, Tumor Necrosis Factor-Alpha, and Matrix Metalloproteinase-8 in Patients with Chronic Peri-Implant Mucositis

Darius Gleiznys; Albertas Kriauciunas; Julius Maminskas; Arturas Stumbras; Dalia Giedrimiene; Christine Niekrash; Alvydas Gleiznys; Jurgina Sakalauskiene; Astra Vitkauskiene

doi:10.12659/MSM.932243

26 October 2021 : Clinical Research

Expression of Interleukin-17, Tumor Necrosis Factor-Alpha, and Matrix Metalloproteinase-8 in Patients with Chronic Peri-Implant Mucositis

Darius Gleiznys^1ABCDEFG*, Albertas Kriauciunas^1BCDE, Julius Maminskas^1AB, Arturas Stumbras^2FG, Dalia Giedrimiene^3CD, Christine Niekrash^4CDE, Alvydas Gleiznys^5AD, Jurgina Sakalauskiene^1ABEF, Astra Vitkauskiene^6ACDE

DOI: 10.12659/MSM.932243

Med Sci Monit 2021; 27:e932243

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Significance of differences in probing depth, plaque index, and marginal bleeding index of healthy subjects, and the mucositis patients untreated and treated groups.

Study groups	Probing depth, mm	Plaque index	Marginal bleeding index
Study groups	Median [25–75%]
HP, n=30	1.4 [1.2–1.6]	0	0
MP, n=30	3.0 [2.8–3.2]	0.6 [0.3–0.8]	0.28 [0.27–0.29]
TP, n=30	2.95 [2.8–3.1]	0.1 [0.06–0.11]	0.03 [0–0.09]
	χ=61,071, df=2, P<0.001	χ=57.95, df=2, P<0.001	χ=65.045, df=2, P<0.001
	<0.001
χ – by Kruskal-Wallis test, multiple comparison by Mann-Whitney test; df – degrees of freedom; HP – healthy subjects; MP – patients with untreated peri-implant mucositis; TP – patients treated with mechanical anti-infective therapies for mucositis.

Back to the Article

Expression of Interleukin-17, Tumor Necrosis Factor-Alpha, and Matrix Metalloproteinase-8 in Patients with Chronic Peri-Implant Mucositis

Your Privacy